Supernus Pharma Balance Sheet - Annual (NASDAQ:SUPN)

Add to My Stocks
$57.05 $1.3 (2.23%) SUPN stock closing price Jun 22, 2018 (Closing)

A thorough fundamental analysis involves using data from Supernus Pharma balance sheet, apart from other financial statements, to value the business. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Supernus Pharma stock analysis. Good annual results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Supernus Pharma balance sheet indicates an asset turnover ratio of 0.58 and debt to equity ratio of 0.9. Also check Supernus Pharma revenue and Supernus Pharma operating cash flow for the same period.

View latest 10 year balance sheet data to check Supernus Pharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec20172016201520142013201220112010
Marketable Securities39.73M23.72M28.03M37.94M49.21M48.48M--
Raw Materials2.99M2.09M2.88M2.49M3.89M1.15M--
Work In Progress8.87M8.87M3.94M6.32M1.34M---
Finished Goods4.43M5.83M5.75M4.62M1.9M---
Notes Receivable--------
Other Current Assets6.52M2.95M5.29M3.84M2.28M1.12M--
Total Current Assets
Property Plant & Equipment14.47M12.44M10.84M8.73M8.14M6.49M5.74M-
Accumulated Depreciation9.34M8.09M6.96M6.29M5.59M5.07M4.43M-
Net Property Plant & Equipment
Investment & Advances133.63M75.41M55M19.81M8.75M---
Other Non-Current Assets--------
Deferred Charges20.84M61.58M22.5M-1M-2.05M-
Deposits & Other Assets--------
Total Assets
Notes Payable-----11.8M6.77M-
Accounts Payable6.84M8.05M4.31M1.86M18.31M10.66M11.76M-
Current Portion Long-Term Debt--------
Current Portion Capital Leases--------
Accrued Expenses111.58M69.37M51.6M25.48M----
Income Taxes Payable--------
Other Current Liabilities4.57M3.31M--8.08M---
Total Current Liabilities
Deferred Taxes/Income1.14M1.5M1.39M1.27M1.41M---
Convertible Debt-4.16M7.18M26.94M34.39M---
Long-Term Debt-----11.08M22.71M-
Non-Current Capital Leases--------
Other Long-Term Liabilities32.83M31.4M5.17M10.44M15.32M2.03M2.34M-
Total Liabilities
Minority Interest--------
Preferred Stock--------
Common Stock Net--------
Capital Surplus294.99M276.12M263.95M230.12M211.95M143.85M49.36M-
Retained Earnings-26.82M-84.28M-144.64M-158.65M-178.52M-86.25M-39.97M-
Treasury Stock--------
Other Liabilities-0.74M-0.13M-0.48M-0.15M--0.05M--
Shareholders Equity267.48M191.75M118.87M71.35M33.46M57.57M9.44M-
Total Liabilities & Shareholders Equity424.46M309.56M188.73M137.5M110.99M93.98M53.73M-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Most investors just check the Supernus Pharma stock price, and Supernus Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Supernus Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: SUPN total assets, which was at $424.46M for 2017 is a balance sheet item representing value of what Supernus Pharma owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Supernus Pharma is $156.98M. Shareholders' equity comes under liabilities as it is money the company owes the holders of SUPN stock.

Supernus Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio